Solid fat nanoemulsions as drug delivery vehicles
AssigneePharmos Corporation
InventorsShimon Amselem, Doron Friedman
Life of this patent
Estimating the term…
Abstract
The present invention provides pharmaceutical compositions comprising nanoemulsions of particles comprising a lipid core which is in a solid or liquid crystalline phase at 25.degree. C, stabilized by at least one phospholipid envelope, for the parenteral, oral, intranasal, rectal, or topical delivery of both fat-soluble and water-soluble drugs. Particles have a mean diameter in the range of 10 to 250 nm. A wide variety of drugs and oxygen transporting perfluorocarbons may be encapsulated in the particles. In addition to drug delivery vehicles, the invention provides oxygen transporting blood substitutes, and nanoemulsions for extracorporeal maintenance of tissues prior to transplantation.
Claims54
A pharmaceutical composition comprising a nanoemulsion of a plurality of noncellular lipid particles having a mean diameter of about 10 to 250 nm in a pharmaceutically acceptable carrier solution, wherein each said lipid particle has a core of a lipid which is in a solid phase at a temperature of at least about 25.degree. C. said lipid core being surrounded by at least one phospholipid bilayer, said bilayer comprising two phospholipid layers separated by an aqueous compartment.
A pharmaceutical composition for parenteral administration of an oxygen transporting perfluorocarbon comprising a nanoemulsion of a plurality of noncellular lipid particles having a mean diameter of about 10 to 250 nm in a pharmaceutically acceptable carrier solution, wherein each said lipid particle has a core of a lipid which is in a solid phase at a temperature of at least about 25.degree. C., wherein said lipid core contains an oxygen transporting perfluorocarbon and is surrounded by at least one phospholipid bilayer, said bilayer comprising two phospholipid layers separated by an aqueous compartment.
A pharmaceutical composition comprising dehydrated lipid particles containing a drug for administration as a nanoemulsion, wherein each of said lipid particles has a core of a lipid which is in a solid phase at a temperature of at least about 25.degree. C. and which is surrounded by at least one phospholipid bilayer, and further wherein, upon rehydration, said lipid particles have a mean diameter of about 10 to 250 nm and said bilayer, said bilayer comprising two phespholipid layers separated by an aqueous compartment.
A pharmaceutical composition for instillation into the eye comprising a nanoemulsion of a plurality of noncellular lipid particles having a mean diameter of about 10 to 250 nm in an optically compatible carrier solution, wherein each said lipid particle has a core of a lipid which is in a solid phase at a temperature of at least about 25.degree. C., said lipid core being surrounded by at least one phospholipid bilayer, said bilayer comprising two phospholipid layers separated by an aqueous compartment.
A blood substitute for maintaining viability of living tissue comprising a nanoemulsion of a plurality of noncellular lipid particles having a mean diameter of about 10 to 250 nm in a physiologically compatible carrier solution, wherein each said lipid particle comprises a lipid core composed of a lipid which is in a solid or liquid crystalline phase at at least about 25.degree. C. as determined in bulk, wherein said lipid core contains an oxygen transporting perfluorocarbon and is surrounded by at least one surface layer containing a phospholipid bilayer.
Dependencies are inferred from the claim text.